

INFECTION CONTROL^{AND}

HOSPITAL EPIDEMIOLOGY

Volume 11, Number 7 • July 1990

EDITORIAL POLICY STATEMENT

- Duplicate Publication of a Manuscript** 341
Richard P. Wenzel, MD, MSc;
Dennis G. Maki, MD; Sue Crow, MSN, RN, CIC;
William Schaffner, MD; John E. McGowan, Jr., MD

ORIGINAL ARTICLES

- Control of Epidemic Methicillin-Resistant
*Staphylococcus aureus*** 343
Katherine A. Murray-Leisure, MD; Sandra Geib, RN;
Diane Graceley; Arline B. Rubin-Slutsky, RN;
Narendra Saxena, MD; H. Arnold Muller, MD;
Bruce H. Hamory, MD
- Adverse Exposures and Universal Precautions
Practices Among a Group of Highly Exposed
Health Professionals** 351
Mary E. Willy, MPH, BSN; Gita L. Dhillon, MS, CNM;
Nancy L. Loewen, MS, CNM; Robert A. Wesley, PhD;
David K. Henderson, MD

SPECIAL COMMENTARIES

- The Influenza Vaccination Demonstration
Project: An Expanded Policy Goal** 357
David S. Fedson, MD
- Infection Control for Home Health
Bryan Simmons, MD; Martha Trusler, RN;** 362
Jane Roccaforte, MD; Philip Smith, MD;
Rebecca Scott, RN

AIDS

- Risky Business: Using Necessarily Imprecise
Casualty Counts to Estimate Occupational
Risks for HIV-I Infection** 371
Susan E. Beekmann, BS; Barbara J. Fahey, BSN;
Julie L. Gerberding, MD; David K. Henderson, MD

EMPORIATRICS

- Emporiatrics: Protecting Travelers From Malaria** 380
Mary D. Nettleman, MD

STATISTICS FOR HOSPITAL EPIDEMIOLOGY

- Practical Considerations in Designing Data
Collection Forms** 384
Patricia A. Wasek, BA

LETTERS TO THE EDITOR

- Pseudoepidemic of *Rhodotorula rubra* in
Patients Undergoing Fiberoptic Bronchoscopy** 334
Marian Kennedy, RN
(Reply) William A. Rutala, PhD;
Karen K. Hoffmann, RN, MS; David J. Weber, MD

- On Duplicate Publication of a Manuscript** 336
W.H. Seto, MD; S.G. Ong, MD; T.Y. Ching, RN

- SHEA NEWSLETTER** 391

From SmithKline Biologicals/
Smith Kline & French Laboratories

Engerix-B[®]

Hepatitis B Vaccine (Recombinant)

0, 1, 2 Month Dosing Regimen for Certain Populations*

**20 mcg recombinant
dose helps to ensure
immune response
in adult patients of
all ages**

**Choice of dosing
regimens**

Adult dose (mcg)

Standard dosing regimen (0, 1 and 6 months)

New 0, 1, 2 month dosing regimen for certain populations*

Published efficacy data: Neonates born of infected mothers[†]

VACTRAC[™]—computer software for vaccination tracking and compliance

Bar-coded, unit-dose vials

Lowest cost per dose[‡]

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

†Hepatitis B Vaccine (Recombinant), MSD.

‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beckman Corporation, 1990

Lowest Cost Per Dose²

Extensively Tested and Well Tolerated[‡]


State-of-the-art recombinant technology

14 million doses distributed in over 87 countries³

Switch to 'Engerix-B'

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine^{3,4}

Engerix-B [®]	Recombivax HB ^{®†}
20	10
Yes	Yes
Yes	No
Yes	Yes
Yes	No
Yes	No
Yes	No



Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
Smith Kline French Laboratories
Philadelphia, PA 19101

Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SK&F literature or PDR. The following is a brief summary.

INDICATIONS AND USAGE: Engerix-B® is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are or will be, at increased risk of exposure to hepatitis B virus.

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

WARNINGS: Do not give additional injections to patients experiencing hypersensitivity after an Engerix-B® injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had a unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

PRECAUTIONS: General: As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection.

Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with Engerix-B®. It is also not known whether Engerix-B® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give Engerix-B® to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether Engerix-B® is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving Engerix-B® to a nursing woman.

Pediatric Use: Engerix-B® has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well. Maternally transferred antibodies do not interfere with the active immune response to the vaccine.

ADVERSE REACTIONS: Engerix-B® is generally well tolerated. During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between Engerix-B® and plasma-derived vaccines. In 36 clinical studies a total of 13,495 doses of Engerix-B® were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of Engerix-B®. Using a symptom checklist,* the most frequently reported adverse reactions were injection site soreness (22%), and fatigue* (14%). Other reactions are listed below.

Incidence 1% to 10% of Injections: Induration, erythema; swelling, fever (> 37.5%); headache*, dizziness*.

*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

Incidence < 1% of Injections: Pain; pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain; cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of Engerix-B® outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

Potential Adverse Experiences: In addition, certain other adverse experiences not observed with Engerix-B® have been reported with Heptavax-B®† and/or Recombivax HB®‡. Those listed below are to serve as alerting information to physicians: Optic neuritis.

HOW SUPPLIED: 20 mcg/mL in Single-Dose Vials in packages of 1, 10 and 25 vials.

NDC 0007-3860-01 (package of 1)
NDC 0007-3860-11 (package of 10)
NDC 0007-3860-16 (package of 25)

10 mcg/0.5 mL in Single-Dose Vials in packages of 1 vial.

NDC 0007-3859-01 (package of 1)

† plasma-derived, Hepatitis B Vaccine, MSD
‡ yeast-derived, Hepatitis B Vaccine, MSD

Manufactured by SmithKline Biologicals, Rixensart, Belgium
Distributed by J. M. SmithKline & French Laboratories
Division of SmithKline Beckman Corp., Philadelphia, PA 19101

Date of issuance: Aug 1939

BAS-EB L6

© SmithKline Beckman Corporation, 1989

Engerix-B is a registered trademark of SmithKline Beckman Corporation.

References:


1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281.
2. Based on Medi-Span® Hospital Formulary Pricing Guide, December 1989.
3. Data on file, SK&F.
4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989; 10:689.


HATS OFF TO FIRST CLASS SERVICE


At SLACK Incorporated we believe our subscribers are first class people. That's why we do everything possible to publish first class journals. And, that's why we maintain a TOLL-FREE CUSTOMER SERVICE HOTLINE. For the first class customer service you deserve, call:


1-800-257-8290


Talk to a SLACK Customer Service Representative about:

 Subscriptions. Subscribing by phone is quick and easy; it only takes a minute and Visa and Mastercard are accepted.

 Renewals. Early subscription renewal helps avoid possible interruptions in service.

 Change of Address. Please notify us four weeks in advance to assure prompt delivery to your new address.

 Questions or Problems. Delivery problems or questions about your subscriptions can be handled instantly.



SLACK

6900 Grove Road,
Thorofare, NJ 08086

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

EDITORIAL POLICY STATEMENT	Duplicate Publication of a Manuscript	341
	Richard P. Wenzel, MD, MSc; Dennis G. Maki, MD; Sue Crow, MSN, RN, CIC; William Schaffner, MD; John E. McGowan, Jr., MD;	
ORIGINAL ARTICLES	Control of Epidemic Methicillin-Resistant <i>Staphylococcus aureus</i>	343
	Katherine A. Murray-Leisure, MD; Sandra Geib, RN; Diane Graceley; Arline B. Rubin-Slutsky, RN; Narendra Saxena, MD; H. Arnold Muller, MD; Bruce H. Hamory, MD	
	Adverse Exposures and Universal Precautions Practices Among a Group of Highly Exposed Health Professionals	351
	Mary E. Willy, MPH, BSN; Gita L. Dhillon, MS, CNM; Nancy L. Loewen, MS, CNM; Robert A. Wesley, PhD; David K. Henderson, MD	
SPECIAL SECTIONS	Special Commentaries	357
	The Influenza Vaccination Demonstration Project: An Expanded Policy Goal	
	David S. Fedson, MD	
	Infection Control for Home Health	362
	Bryan Simmons, MD; Martha Trusler, RN; Jane Roccaforte, MD; Philip Smith, MD; Rebecca Scott, RN	
	AIDS	371
	Risky Business: Using Necessarily Imprecise Casualty Counts to Estimate Occupational Risks for HIV-1 Infection	
	Susan E. Beekmann, BS; Barbara J. Fahey, BSN; Julie L. Gerberding, MD; David K. Henderson, MD	
	Emporiatics	380
	Emporiatics: Protecting Travelers From Malaria	
	Mary D. Nettleman, MD	
	Statistics for Hospital Epidemiology	384
	Practical Considerations in Designing Data Collection Forms	
	Patricia A. Wasek, BA	
DEPARTMENTS	Letters to the Editor	334
	Calendar of Events	390
	SHEA Newsletter	391
	Classified Marketplace	Cover 3

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated 6900 Grove Road Thorofare New Jersey 08086 Telephone (609) 848-1000

Copyright 1990: All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

Subscriptions: Requests should be addressed to the publisher (except Japan) Japan contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the US and possessions: Individual One year—\$60.00. Two years—\$95.00. Three years—\$125.00. Institutional One year—\$70.00. Two years—\$110.00. Three years—\$150.00. Canada \$18.00 additional each year. All other countries \$30.00 additional each year. Single copies of current issues may be obtained for \$8.00, United States and possessions; \$16.00 all other countries.

Reprints: All requests to reprint or use material published herein should be addressed to Lester J. Robeson, SLACK Incorporated, 6900 Grove Road Thorofare, NJ 08086. For reprint orders and prices contact Fran Micalletti at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy plus 5¢ per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes or for creating new collective works.

Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. Postmaster: Send address changes to SLACK Incorporated, 6900 Grove Road Thorofare, NJ 08086.

As of Volume 1 Number 1 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents—Clinical Practice Hospital Literature index Cumulative Index to Nursing and Allied Health Literature and Nursing Abstracts.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
 A-1131 Medical Center North
 Nashville, TN 37232-2637
 (615) 343-1095; (615) 343-1882 (FAX)
 Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL ADVISORY BOARD

- Jacques F. Acar, MD Paris, France
 J. Wesley Alexander, MD Cincinnati, Ohio
 Paul Arnow, MD Chicago, Illinois
 Graham A.J. Ayliffe, MD Birmingham, United Kingdom
 Neil L. Barg, MD Yakima, Washington
 Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia
 John M. Boyce, MD Providence, Rhode Island
 Professor Dr. Ilja Braveny Munich, Federal Republic of Germany
 Charles Bryan, MD Columbia, South Carolina
 Christian Brun-Buisson, MD Creteil, France
 Donald E. Craven, MD Boston, Massachusetts
 Sue Crow, MSN, RN, CIC Shreveport, Louisiana
 Franz Daschner, MD Freiburg, Federal Republic of Germany
 Leigh G. Donowitz, MD Charlottesville, Virginia
 Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin
 Theodore C. Eickhoff, MD Denver, Colorado
 Bruce Farber, MD Manhasset, New York
 Victoria J. Fraser, MD St. Louis, Missouri
 Peter C. Fuchs, MD, PhD Black Butte, Oregon
 Richard A. Garibaldi, MD Farmington, Connecticut
 Velvl Greene, PhD, MPH Beer Sheva, Israel
 Robert Gaynes, MD Atlanta, Georgia
 David W. Gregory, MD Nashville, Tennessee
 David K. Henderson, MD Bethesda, Maryland
 Peter N.R. Heseltine, MD Los Angeles, California
 Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina
 Marguerite McMillan Jackson, RN, PhD San Diego, California
 Janine Jagger, MPH, PhD Charlottesville, Virginia
 William R. Jarvis, MD Atlanta, Georgia
 Douglas S. Kernodle, MD Nashville, Tennessee
 Robert H. Latham, MD Nashville, Tennessee
 Lewis B. Lefkowitz, MD Nashville, Tennessee
 Hsieh-Shong Leu, MD, MSc Taipei, Taiwan
 Jack Levy, MD Brussels, Belgium
 Victor Lorian, MD Bronx, New York
 Dennis G. Maki, MD Madison, Wisconsin
 Professor Dr. Walter Marget Munich, Federal Republic of Germany
 William J. Martone, MD Bethesda, Maryland
 Allison McGeer, MD Toronto, Ontario, Canada
 John E. McGowan, Jr., MD Atlanta, Georgia
 Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada
 Raf Mertens, MD Brussels, Belgium
 Robert R. Muder, MD Pittsburgh, Pennsylvania
 Joseph M. Mylotte, MD, CIC Buffalo, New York
 Lindsay Nicolle, MD Winnipeg, Manitoba, Canada
 Juhani Ojajarvi, MD Helsinki, Finland
 Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota
 Jan Evans Patterson, MD San Antonio, Texas
 Sindy M. Paul, MD Trenton, New Jersey
 Michael A. Pfaller, MD Iowa City, Iowa
 Samuel Ponce de Leon, MD, MSc Mexico City, Mexico
 Isaam Raad, MD Houston, Texas
 Manfred L. Rotter, MD, DipBact Vienna, Austria
 Theodore Sacks, MD Jerusalem, Israel
 William E. Scheckler, MD Madison, Wisconsin
 Kent Sepkowitz, MD New York City, New York
 Denis Spelman, MD Prahran Victoria, Australia
 Michael L. Tapper, MD New York, New York
 Clyde Thornsberry, PhD Brentwood, Tennessee
 Professor Leonid P. Titov Minsk, Republic of Belarus
 Timothy R. Townsend, MD Millwood, Virginia
 Antoni Trilla, MD, PhD Barcelona, Spain
 Professor Wang Shu-Qun Beijing, People's Republic of China
 J. John Weems, Jr., MD Greenville, South Carolina
 Robert A. Weinstein, MD Chicago, Illinois
 Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany
 Sergio B. Wey, MD São Paulo, Brazil
 Rebecca Wurtz, MD Evanston, Illinois

SLACK Incorporated

6900 Grove Road
 Thorofare, New Jersey 08086
 (609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCC

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane

Classified/Recruitment Sales Manager

Michele Burch

"Synergism.."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantially less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temperature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77° F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

* *Journal of Clinical Microbiology*,
November 1985, p. 735 - 739



Sporicidin
INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847